Lepu Medical expands its biotech footprint through a licensing deal with Sidera Bio for MWN105, a triple-agonist drug targeting obesity and metabolic disorders, combining equity, milestone, and royalty gains in a global partnership.
Manifold Bio inks a groundbreaking collaboration with Roche to apply AI-guided brain-shuttle technology for neurological therapies.
The New Frontier of Gene Editing: From Precision Tools to Personalized Therapies A new generation of programmable gene editing tools is pushing biotechnology toward an era of truly personalized medicine one in which therapies are tailored not only to specific diseases but to individual genetic profiles. As highlighted in a recent npj Biomedical Innovations feature … Read more
Pfizer’s GLP-1 lawsuit tests biosimilar ambitions and contract guardrails.
ICER pegs an ~$88K benchmark for brensocatib and spotlights evidence gaps shaping NCFB access.
Novo’s unsolicited Metsera bid could upend Pfizer pact and reshape the GLP-1 race.
In a transformative week for market access, the CMS and Europe reimbursement pathway expansion delivered several pivotal coverage and pricing decisions reshaping patient access across cardiovascular, hepatic, and oncology therapies. From CMS’s national determinations on breakthrough devices to European HTA approvals in rare disease and cancer, these developments underscore a growing transatlantic alignment between regulators … Read more
Funeral reimbursement could transform U.S. organ donation access and equity.
Evernorth’s pricing model overhaul transforms drug access and reimbursement dynamics.
Successful reimbursement milestone strengthens device adoption and access strategy.